Job Trends
No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
THE LATEST
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) has been approved for 21 indications, but you’d better keep up, because it seems the drug is approved for some new indication or combination just about every week.
Scot Ebbinghaus, Vice President and Therapeutic Area Head, Oncology Clinical Research, Merck Research Laboratories, took time out ahead of the meeting to discuss three of the company’s clinical trials being presented and the implications for oncology patients and Merck.
Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.
The data-manipulation scandal with Novartis is widening, undermining investors’ trust in company chief executive officer Vas Narasimhan.
Saranas Inc. announced that it has been named one of Houston’s most innovative companies.
Neos Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2019 and provided a business update.
For 8-million adults who suffer from post-traumatic stress disorder in any given year, medication and cognitive therapy have been the treatment protocol.
Myriad Genetics, Inc. announced that the AstraZeneca/Merck Phase III PROfound studydemonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza®, a novel PARP inhibitor.
Finding Could Lead to Better Clinical Disease Monitoring
Crucial Data Solutions, a provider of innovative technologies to advance clinical research, announced that industry veteran Jeff Rogers has joined the company as President.